CI Investments Inc. grew its stake in IQVIA Holdings Inc. (NYSE:IQV – Free Report) by 57.0% in the 1st quarter, HoldingsChannel reports. The institutional investor owned 176,021 shares of the medical research company’s stock after buying an additional 63,900 shares during the period. CI Investments Inc.’s holdings in IQVIA were worth $30,019,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors also recently made changes to their positions in the company. Danica Pension Livsforsikringsaktieselskab bought a new stake in IQVIA in the first quarter valued at approximately $36,012,000. ABN Amro Investment Solutions increased its position in shares of IQVIA by 51.1% during the first quarter. ABN Amro Investment Solutions now owns 9,557 shares of the medical research company’s stock worth $1,630,000 after buying an additional 3,234 shares during the period. Oslo Pensjonsforsikring AS bought a new position in IQVIA during the first quarter worth $347,000. Andra AP fonden lifted its holdings in IQVIA by 320.1% in the first quarter. Andra AP fonden now owns 121,405 shares of the medical research company’s stock valued at $20,704,000 after buying an additional 92,505 shares during the period. Finally, Leith Wheeler Investment Counsel Ltd. bought a new stake in IQVIA during the first quarter valued at $285,000. 89.62% of the stock is owned by institutional investors and hedge funds.
Wall Street Analyst Weigh In
Several research analysts have recently weighed in on the company. Robert W. Baird lifted their price objective on IQVIA from $230.00 to $249.00 and gave the stock an “outperform” rating in a research report on Wednesday, July 1st. Morgan Stanley restated an “equal weight” rating and set a $200.00 price target (down from $225.00) on shares of IQVIA in a report on Wednesday, June 17th. HSBC reiterated a “buy” rating and issued a $240.00 price objective on shares of IQVIA in a research note on Monday, July 6th. Deutsche Bank Aktiengesellschaft set a $240.00 target price on shares of IQVIA in a research report on Thursday, July 9th. Finally, Evercore restated an “outperform” rating and issued a $185.00 price target on shares of IQVIA in a report on Wednesday, April 8th. Thirteen equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $225.71.
IQVIA Price Performance
IQV stock opened at $198.96 on Thursday. The company has a market capitalization of $33.21 billion, a P/E ratio of 24.65, a price-to-earnings-growth ratio of 1.81 and a beta of 1.20. The business has a 50-day simple moving average of $186.73 and a two-hundred day simple moving average of $187.36. IQVIA Holdings Inc. has a 52-week low of $154.50 and a 52-week high of $247.04. The company has a debt-to-equity ratio of 2.20, a quick ratio of 0.75 and a current ratio of 0.75.
IQVIA (NYSE:IQV – Get Free Report) last issued its quarterly earnings data on Tuesday, May 5th. The medical research company reported $2.90 earnings per share for the quarter, beating the consensus estimate of $2.83 by $0.07. The business had revenue of $4.15 billion for the quarter, compared to analysts’ expectations of $4.10 billion. IQVIA had a return on equity of 30.50% and a net margin of 8.33%.The business’s revenue was up 8.4% on a year-over-year basis. During the same period last year, the business earned $2.70 EPS. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. Research analysts expect that IQVIA Holdings Inc. will post 11.57 EPS for the current fiscal year.
IQVIA declared that its Board of Directors has initiated a share repurchase plan on Thursday, May 7th that allows the company to repurchase $2.00 billion in shares. This repurchase authorization allows the medical research company to buy up to 6.8% of its stock through open market purchases. Stock repurchase plans are generally a sign that the company’s board of directors believes its shares are undervalued.
About IQVIA
IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.
IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.
Further Reading
- Five stocks we like better than IQVIA
- Could Truth API Become Trump Media’s First Meaningful Revenue Driver?
- Small Caps Are Crushing the S&P 500—3 Stocks Still Worth Buying
- Moog Is More Than a Missile Maker, and Wall Street Is Noticing
- A Boring Dividend Growth Strategy Becomes a Solid Defensive Play
Want to see what other hedge funds are holding IQV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IQVIA Holdings Inc. (NYSE:IQV – Free Report).
Receive News & Ratings for IQVIA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IQVIA and related companies with MarketBeat.com's FREE daily email newsletter.
